Levocetirizine: The allergist's arsenal grows larger

R. Matthew Bloebaum, J. Andrew Grant

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Antihistamines are the cornerstone of treatment for many allergic diseases, such as allergic rhinitis and chronic urticaria. Since the discovery of their beneficial effects in the 1940s, scientists have found molecules with greater selectivity to block specific histamine receptors without some of the detrimental side effects that are seen if antihistamines cross the blood-brain barrier. Levocetirizine is the active enantiomer of cetirizine and a sective H1-histamine blocker. It exhibits many favourable characteristics of an ideal antihistamine, both pharmacodynamically and pharmacokinetically, including high bioavailability, rapid onset of action, limited distribution and low degree of metabolism. Furthermore, clinical trials indicate that it is safe and effective for the treatment of allergic rhinitis and chronic urticaria with a minimal amount of untoward effects. 2004

Original languageEnglish (US)
Pages (from-to)1581-1588
Number of pages8
JournalExpert Opinion on Pharmacotherapy
Issue number7
StatePublished - Jul 2004
Externally publishedYes


  • Allergic rhinitis
  • Antihistamine
  • Levocetirizine
  • Urticaria

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Levocetirizine: The allergist's arsenal grows larger'. Together they form a unique fingerprint.

Cite this